Upload

Loading icon Loading...

This video is unavailable.

ASH 2010: The role of bendamustine in the treatment of mantle cell lymphomas

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to like ecancer medicalscience's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike ecancer medicalscience's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to add ecancer medicalscience's video to your playlist.

Uploaded on Mar 15, 2011

Prof Mathias Rummel, Klinikum der Justus-Liebig-Universität, Giessen, Germany, discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line treatment for MCL, Prof Rummel outlines his latest results presented at ASH 2010. These results establish the superiority of bendamustine plus rituximab over fludarabine plus rituximab in patients with relapsed MCL in terms of both efficacy and toxicity profile.

Loading icon Loading...

Loading icon Loading...

Loading icon Loading...

The interactive transcript could not be loaded.

Loading icon Loading...

Loading icon Loading...

Ratings have been disabled for this video.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.

Loading icon Loading...

Advertisement
Loading...
Working...
to add this to Watch Later

Add to